6618 (6618) Fair Value & Analysis

Healthcare · Market cap HK$109B

6 6618 6618 · HK

PriceHK$34.16

Fair ValueHK$33.08

Upside-3.2%

Quality58/100

Watch 6618 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$25.27 – HK$41.35

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −14.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$31.98 – HK$69.65 · fair‑value band HK$25.27 – HK$41.35 · the HK$34.16 price screens above the HK$33.08 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6618 (6618) currently trades at HK$34.16, while our model-based Fair Value estimate is HK$33.08 — implying the stock looks roughly 3.2% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6618 generated revenue of HK$73.4B at a net margin of 7.3%. Revenue grew 28.0% year over year. It earns a return on equity of 9.3%. The balance sheet holds a net cash position of HK$31.2B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$73.4B

Revenue growth (YoY) +28.0%

Net margin 7.3%

Return on equity 9.3%

Free cash flow HK$9.8B FY2025

P/E ratio 17.6

More key figures

Operating margin 4.4%

EPS (TTM) HK$0.8100

EPS growth (YoY) +29.8%

Net cash HK$31.2B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6618 reported revenue of HK$73.4B in FY2025 versus HK$30.7B in FY2021, a compound +24.4%/yr. Reported net income was HK$5.4B in FY2025.

Revenue +24.4%/yr

FY21 HK$30.7B

FY22 HK$46.7B

FY23 HK$53.5B

FY24 HK$58.2B

FY25 HK$73.4B

Net income

FY21 −HK$1.1B

FY22 HK$380M

FY23 HK$2.1B

FY24 HK$4.2B

FY25 HK$5.4B

Is 6618 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
JD Health International Inc JDHIY	$4.55	$8.78	+93%
Alibaba Health Information Technology Limited ALBBY	$8.27	$6.61	-20%
0241 0241	HK$3.08	HK$2.04	-34%
Raia Drogasil S.A RADL3	R$17.76	R$14.97	-16%
Yifeng Pharmacy Chain Co 603939	¥19.75	¥40.59	+106%
Clicks Group CLCGY	$27.97	$34.29	+23%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6618 (6618) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$33.08 versus a price of HK$34.16 — about −3% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6618?

Our model-based fair value for 6618 is HK$33.08 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$34.16.

What is the quality score of 6618?

6618 has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6618 (6618)?

6618 reported trailing-twelve-month revenue of about HK$73.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6618?

The net profit margin of 6618 is about 7.3%, meaning it keeps roughly 7.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.